Literature DB >> 20541775

Dysregulated neurotrophin mRNA production by immune cells of patients with relapsing remitting multiple sclerosis.

Nataly Urshansky1, Karin Mausner-Fainberg, Eitan Auriel, Keren Regev, Firas Farhum, Arnon Karni.   

Abstract

Recent studies have suggested a neuroprotective activity of the lesion-infiltrating immune cells in multiple sclerosis (MS) by secretion of neurotrophins. We had earlier reported that immune cells from relapsing remitting MS (RR-MS) patients secrete low levels of brain-derived neurotrophic factor (BDNF), and that its secretion is dysregulated after CD40 stimulation. Here, we measured mRNA levels for BDNF, NT3 and NGF-beta mRNA in unstimulated PBMCs and found levels lower in untreated RR-MS patients than in healthy controls (HC). T-cell stimulation with anti-CD3/CD28 mAb up-regulated neurotrophin mRNA expression in untreated RR-MS patients and not in HC, whereas stimulation of PBMCs with anti-CD40 mAb up-regulated neurotrophin mRNA expression in HC and not in RR-MS patients. Further cellular analyses of the production of the neurotrophin mRNA in individual cells revealed that T cells were the main producers of the neurotrophin mRNA in RR-MS patients, and that monocytes were the main producers of NT3 and NGF-beta mRNA in HC. BDNF mRNA was similarly produced in monocytes and T cells in the HC group. The cytokines TNF-alpha and IL-17 up-regulated the expression of neurotrophin mRNA in HC but not in RR-MS patients. The neuroprotective activity of PBMCs appeared to be dysregulated in untreated patients with RR-MS, while the differences between the IFN-beta-treated RR-MS patients and the HC were smaller. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20541775     DOI: 10.1016/j.jns.2010.05.019

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

Review 1.  IL-17 and limits of success.

Authors:  Zahra Omidian; Rizwan Ahmed; Adebola Giwa; Thomas Donner; Abdel Rahim A Hamad
Journal:  Cell Immunol       Date:  2018-09-17       Impact factor: 4.868

2.  Differential regulation of macrophage phenotype by mature and pro-nerve growth factor.

Authors:  Kimberly S Williams; Deirdre A Killebrew; Gillian P Clary; Jaimie A Seawell; Rick B Meeker
Journal:  J Neuroimmunol       Date:  2015-05-16       Impact factor: 3.478

3.  Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis.

Authors:  Maya Golan; Karin Mausner-Fainberg; Bassima Ibrahim; Moshe Benhamou; Adi Wilf-Yarkoni; Hadar Kolb; Keren Regev; Arnon Karni
Journal:  CNS Drugs       Date:  2019-12       Impact factor: 5.749

4.  CD11b+GR1+ myeloid cells secrete NGF and promote trigeminal ganglion neurite growth: implications for corneal nerve regeneration.

Authors:  Joy Sarkar; Shweta Chaudhary; Sarmad H Jassim; Okan Ozturk; Wallace Chamon; Balaji Ganesh; Sapna Tibrewal; Sonal Gandhi; Yong-Soo Byun; Joelle Hallak; Dolores L Mahmud; Nadim Mahmud; Damiano Rondelli; Sandeep Jain
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-03       Impact factor: 4.799

5.  Reduced ErbB4 Expression in Immune Cells of Patients with Relapsing Remitting Multiple Sclerosis.

Authors:  Evgenia Tynyakov-Samra; Eitan Auriel; Yifat Levy-Amir; Arnon Karni
Journal:  Mult Scler Int       Date:  2011-09-12

Review 6.  The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.

Authors:  Suzanne A B M Aarts; Tom T P Seijkens; Koos J F van Dorst; Christine D Dijkstra; Gijs Kooij; Esther Lutgens
Journal:  Front Immunol       Date:  2017-12-12       Impact factor: 7.561

7.  Serum and lymphocytic neurotrophins profiles in systemic lupus erythematosus: a case-control study.

Authors:  Anne-Laure Fauchais; Marie-Claude Lise; Pierre Marget; François-Xavier Lapeybie; Holy Bezanahary; Clothilde Martel; Stéphanie Dumonteil; Agnès Sparsa; Fabrice Lalloué; Kim Ly; Marie Essig; Elisabeth Vidal; Marie-Odile Jauberteau
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.